ArticleWorld journal of hepatology2026
Advances in biliary stone management: Latest-generation extracorporeal shock wave lithotripsy
Article in World journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtracorporeal shock wave lithotripsy (ESWL) and laser lithotripsy (LL) are established alternatives for the management of difficult common bile duct (CBD) stones. However, there is limited evidence regarding the efficacy and safety of the latest-generation Dornier Delta III lithotripter. In particular, evidence on the clinical performance of the Dornier Delta III lithotripter is scarce.
aimTo evaluate and compare the efficacy and safety of ESWL performed with the Dornier Delta III and of LL using a single-operator cholangioscope with specific focus on stone clearance rates, number of treatment sessions, and procedure-related adverse events in a large patient cohort.
methodsWe conducted a retrospective analysis of a prospectively maintained database at AIG Hospitals, Hyderabad, covering the period from January 2019 to December 2022. A total of 458 patients with difficult bile duct stones underwent either ESWL or LL based on clinical discretion. ESWL was performed using the Dornier Delta III lithotripter, whereas LL was carried out with a single-operator cholangioscope in combination with an yttrium-aluminum-garnet laser.
resultsThe 387 patients with difficult bile duct stones (mean age 53.8 ± 15.7 years, 58.7% male) underwent ESWL. A single CBD stone was noted in 46.8% of patients while 53.2% patients had multiple stones. Complete duct clearance was achieved in 95.1% of patients, with 68.7% requiring two or more ESWL sessions. Adverse events included cholangitis in 3 patients and post-sphincterotomy bleeding in 4 patients; All were managed conservatively. Seventy-one patients (mean age 55 ± 15.4 years, 64.8% male) underwent LL. Complete duct clearance was achieved in 97.2% of patients with single-session clearance in 58 (81.7%) patients. The remaining 18.3% of patients required two or three sessions for fragmented stone removal. Adverse events included cholangitis in 2 patients and mild pancreatitis in 1 patient; all were managed conservatively. Patients with incomplete clearance were referred for surgery. There was no significant difference in efficacy between ESWL and LL (95.1%
conclusionESWL using the latest generation lithotripter and LL provide equally effective and safe alternatives for managing difficult CBD stones, minimizing the need for surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.